Sanofi | CIK:0001121404 | 3

  • Filed: 3/16/2018
  • Entity registrant name: Sanofi (CIK: 0001121404)
  • Generator: Donnelley Financial Solutions
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/0001193125-18-084834-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/sny-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001121404
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfOperatingSegmentsExplanatory

    The table below sets forth our segment results for the year ended December 31, 2017, based on our new segment reporting model:

     

        2017  
    (€ million)   Pharmaceuticals     Consumer
    Healthcare    		     Vaccines      Other     Total Sanofi  
    Net sales     25,122       4,832       5,101        -       35,055  
    Other revenues     287       -       862        -       1,149  
    Cost of sales     (6,728)       (1,648)       (2,798)        (271)       (11,445)  
    Research and development expenses     (4,056)       (123)       (557)        (736)       (5,472)  
    Selling and general expenses     (5,750)       (1,605)       (698)        (2,005)       (10,058)  
    Other operating income and expenses     34       94       (107)        (17)       4  
    Share of profit/(loss) from investments accounted for using the equity method     233       1       1        -       235  
    Net income attributable to non-controlling interests     (117)       (8)       -        -       (125)  
    Business operating income     9,025       1,543       1,804        (3,029)       9,343  

    Due to lack of available data and the too complex and significant adjustments that would be required (in particular to our reporting tools), the comparative information has not been restated to reflect the changes arising from our new segment reporting model. We have therefore also presented segment results for 2017 and comparative periods using our previous segment reporting model in the table below:

     

        2017  
    (€ million)   Pharmaceuticals(a)     Vaccines(b)     Other     Total Sanofi  
    Net sales     29,954       5,101       -       35,055  
    Other revenues     287       862       -       1,149  
    Cost of sales     (8,628)       (2,817)       -       (11,445)  
    Research and development expenses     (4,835)       (637)       -       (5,472)  
    Selling and general expenses     (9,176)       (881)       (1)       (10,058)  
    Other operating income and expenses     180       (108)       (68)       4  
    Share of profit/(loss) from investments accounted for using the equity method     234       1       -       235  
    Net income attributable to non-controlling interests     (125)       -       -       (125)  
    Business operating income     7,891       1,521       (69)       9,343  

     

      (a)

    Includes Consumer Healthcare and an allocation of global support function costs.

     

      (b)

    Includes an allocation of global support function costs.

     

     

     

    The table below sets forth our segment results for the year ended December 31, 2016, based on our previous segment reporting model:

     

         December 31, 2016  
    (€ million)    Pharmaceuticals(a)      Vaccines(b)      Other      Total Sanofi  
    Net sales      29,244        4,577        -        33,821  
    Other revenues      274        613        -        887  
    Cost of sales      (8,349)        (2,353)        -        (10,702)  
    Research and development expenses      (4,618)        (554)        -        (5,172)  
    Selling and general expenses      (8,743)        (743)        -        (9,486)  
    Other operating income and expenses      (1)        (14)        (112)        (127)  
    Share of profit/(loss) from investments accounted for using the equity method      129        48        -        177  
    Net income attributable to non-controlling interests      (112)        (1)        -        (113)  
    Business operating income      7,824        1,573        (112)        9,285  

     

      (a)

    Includes Consumer Healthcare and an allocation of global support function costs. Consumer Healthcare net sales were €3,330 million in 2016.

     

      (b)

    Includes an allocation of global support function costs.

    The table below sets forth our segment results for the year ended December 31, 2015, based on our previous segment reporting model:

     

         December 31, 2015  
    (€ million)    Pharmaceuticals(a)      Vaccines(b)/(c)      Other      Total Sanofi  
    Net sales      29,799        4,261        -        34,060  
    Other revenues      288        513        -        801  
    Cost of sales      (8,788)        (2,131)        -        (10,919)  
    Research and development expenses      (4,530)        (552)        -        (5,082)  
    Selling and general expenses      (8,656)        (726)        -        (9,382)  
    Other operating income and expenses      (121)        27        (114)        (208)  
    Share of profit/(loss) from investments accounted for using the equity method      146        23        -        169  
    Net income attributable to non-controlling interests      (125)        (1)        -        (126)  
    Business operating income      8,013        1,414        (114)        9,313  

     

      (a)

    Includes Consumer Healthcare and an allocation of global support function costs. Consumer Healthcare net sales were €3,492 million in 2015.

     

      (b)

    Includes an allocation of global support function costs.

     

      (c)

    Due to a change in accounting presentation, VaxServe sales of non-Sanofi products are included in Other revenues from 2016 onwards. The presentation of prior period Net sales and Other revenues has been amended accordingly (see Note B.13.).